EGFR and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), common driver mutations involve EGFR, KRAS, ALK, and BRAF, which activate oncogenic signaling pathways such as PI3K/AKT and RAS/MAPK, promoting uncontrolled cellular proliferation.